There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vor Biopharma (VOR – Research Report), Inotiv (NOTV – Research Report) and Vericel (VCEL – Research Report) with bullish sentiments.
Vor Biopharma (VOR)
In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Vor Biopharma, with a price target of $18.00. The company’s shares closed last Monday at $2.04, close to its 52-week low of $1.62.
According to TipRanks.com, Walsh is a 2-star analyst with an average return of
Vor Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $14.69, a 649.5% upside from current levels. In a report issued on March 21, H.C. Wainwright also maintained a Buy rating on the stock with a $17.50 price target.
See the top stocks recommended by analysts >>
Inotiv (NOTV)
In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on Inotiv, with a price target of $10.00. The company’s shares closed last Monday at $11.04, close to its 52-week high of $11.26.
According to TipRanks.com, Takkinen is a 4-star analyst with an average return of
Currently, the analyst consensus on Inotiv is a Strong Buy with an average price target of $10.75, representing a 0.3% upside. In a report released yesterday, Craig-Hallum also maintained a Buy rating on the stock.
Vericel (VCEL)
In a report released today, Samuel Brodovsky from Truist Financial upgraded Vericel to Buy. The company’s shares closed last Monday at $47.94, close to its 52-week high of $50.09.
According to TipRanks.com, Brodovsky ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Vericel is a Strong Buy with an average price target of $51.10, representing an 8.6% upside. In a report issued on March 21, Leerink Partners also reiterated a Buy rating on the stock with a $51.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VOR:
- Vor Bio price target lowered to $12 from $15 at Stifel
- Vor Bio price target lowered to $15 from $17 at Oppenheimer
- Vor Bio reports Q4 EPS (39c), consensus (50c)
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- VOR Upcoming Earnings Report: What to Expect?
